BIIB Related Company Press Releases

May 23, 2013 08:00 AM Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer

May 22, 2013 04:01 PM Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference

May 21, 2013 05:00 AM RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market

May 21, 2013 04:30 AM Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis

May 13, 2013 07:30 AM FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A

May 13, 2013 05:00 AM RBCC Partner n3D Signs U.S. Distribution Agreement

May 6, 2013 05:00 AM World’s Premiere Science Journal Touts Revolutionary Innovations by RBCC Partner Nano3D

Apr 30, 2013 05:00 AM RBCC: Personalized Medicine Poised to Revolutionize Insurance & Pharmaceuticals

Apr 25, 2013 06:30 AM Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013

Apr 24, 2013 05:00 AM RBCC Looks Overseas for Potentially Lucrative Licensing Opportunities

Apr 15, 2013 04:28 AM RBCC Nears Deal With Leading Genetic Testing Lab

Apr 10, 2013 04:01 PM Biogen Idec to Report First Quarter 2013 Financial Results on April 25, 2013

Apr 4, 2013 08:15 AM The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis

Apr 2, 2013 04:30 PM Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®

Apr 2, 2013 05:26 AM RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow

Mar 27, 2013 04:23 PM Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis

Mar 27, 2013 04:10 PM Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis

Mar 26, 2013 05:00 AM RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing